Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Hugosson

Showing results (11-20 of 201) with videos related to

Pageof 21
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Radical retropubic prostatectomy: a review of outcomes and side-effectsJonas Hugosson, Johan Stranne, Sigrid V Carlsson
The New England Journal of Medicine|December 12, 2024
Four Years of Screening for Prostate Cancer with PSA and MRI. ReplyJonas Hugosson, Rebecka Arnsrud Godtman, Johan Stranne
European Urology|May 24, 2016
Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8Rebecka Arnsrud Godtman, Johan Stranne, Jonas Hugosson
European Urology|September 25, 2025
Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380Emmeli Palmstedt, Jonas Hugosson, Rebecka Arnsrud Godtman
Scandinavian Journal of Urology and Nephrology|July 16, 2005
Prostate biopsy and anaesthesia: an overviewGunnar Aus, Jan-Erik Damber, Jonas Hugosson
Evidence-Based Medicine|January 14, 2011
Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductionsMonique J Roobol, Sigrid Carlsson, Jonas Hugosson
European Urology Open Science|May 28, 2026
Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)Marianne Månsson, Kirsi Talala, Anssi Auvinen, et al.
Scandinavian Journal of Urology and Nephrology|April 6, 2011
High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithmRebecka Godtman, Erik Holmberg, Johan Stranne, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2007
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised studySigrid Carlsson, Gunnar Aus, Catrin Wessman, et al.
European Urology|January 31, 2012
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancerMaciej Kwiatkowski, Laurence Klotz, Jonas Hugosson, et al.
Pageof 21

Showing results (11-20 of 201) with videos related to

Sort By:
Pageof 21
Acta Oncologica (Stockholm, Sweden)|May 25, 2011
Radical retropubic prostatectomy: a review of outcomes and side-effectsJonas Hugosson, Johan Stranne, Sigrid V Carlsson
The New England Journal of Medicine|December 12, 2024
Four Years of Screening for Prostate Cancer with PSA and MRI. ReplyJonas Hugosson, Rebecka Arnsrud Godtman, Johan Stranne
European Urology|May 24, 2016
Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8Rebecka Arnsrud Godtman, Johan Stranne, Jonas Hugosson
European Urology|September 25, 2025
Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380Emmeli Palmstedt, Jonas Hugosson, Rebecka Arnsrud Godtman
Scandinavian Journal of Urology and Nephrology|July 16, 2005
Prostate biopsy and anaesthesia: an overviewGunnar Aus, Jan-Erik Damber, Jonas Hugosson
Evidence-Based Medicine|January 14, 2011
Meta-analysis finds screening for prostate cancer with PSA does not reduce prostate cancer-related or all-cause mortality but results likely due to heterogeneity - the two highest quality studies identified do find prostate cancer-related mortality reductionsMonique J Roobol, Sigrid Carlsson, Jonas Hugosson
European Urology Open Science|May 28, 2026
Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC)Marianne Månsson, Kirsi Talala, Anssi Auvinen, et al.
Scandinavian Journal of Urology and Nephrology|April 6, 2011
High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithmRebecka Godtman, Erik Holmberg, Johan Stranne, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2007
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised studySigrid Carlsson, Gunnar Aus, Catrin Wessman, et al.
European Urology|January 31, 2012
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancerMaciej Kwiatkowski, Laurence Klotz, Jonas Hugosson, et al.
Pageof 21